bullish
Abbott Laboratories (ABT US): Q42021 Review- Conservative Guidance Leaves Room For Upside Potential
171 Views27 Jan 2022 23:27
SUMMARY
- Abbott Laboratories (ABT US) Q4 revenue and adjusted EPS beat consensus. Global COVID-19 testing-related sales were $2.3 billion, ahead of consensus of $1.3 billion.
- Management provided conservative guidance for 2022 COVID-19 testing revenue of $2.5 billion, which is expected to be updated on a quarterly basis.
- Abbott expects its medical devices business on a normal run rate in H2 2022. However, its diabetes care portfolio remained resilient and grew faster than the nearest competitor.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Sri Lanka Defaults on Debt: South Korea Is the Biggest Investor & Domino Effect on Other Countries?19 May 2022
- India Bans Wheat Exports; Baby Formula & Diesel Shortage in US: Repeat of Beggar Thy Neighbor Policy18 May 2022
- Abbott Laboratories (ABT US): 2022 High Conviction Idea 1Q22 Review- COVID Testing Bonanza Continues21 Apr 2022
- Abbott Laboratories (ABT US): Q42021 Review- Conservative Guidance Leaves Room For Upside Potential27 Jan 2022
- 2022 High Conviction: Abbott Laboratories – Resilient Business Model at Reasonable Valuation02 Dec 2021
x